GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , Sept. 15, 2023 /PRNewswire/ -- TO: RECORD AND BENEFICIAL HOLDERS OF GW PHARMACEUTICALS, PLC.

Monteverde & Associates PC and Kahn Swick & Foti Announce Proposed Class Action Settlement on Behalf of Holders of GW Pharmaceuticals PLC American Depositary Shares

Aurora Cannabis

AFC Gamma

Beyond Meat

Cara Therapeutics

Canopy Growth

Amplify Seymour Cannabis ETF

Cronos Group

Direxion Daily CSI China Internet Index Bull 2X Shares

Flora Growth Corp

GrowGeneration Corp

High Tide

Hydrofarm Holdings Group

Innovative Industrial Properties

Intercure Ltd

ETFMG Alternative Harvest ETF

Cannabis REITs have been slammed this year amid concern over defaults from their cannabis cultivator tenants, which have been smoked by plunging wholesale cannabis prices and setbacks on federal legalization. The exclusion of the SAFE Banking Act from the omnibus federal spending package dimmed the once-high hopes that major federal marijuana legislation would be passed during the Biden Presidency.

Cannabis REITs: Smoked Out

Adobe

Atai Life Sciences BV

COMPASS Pathways

Cybin

Delta Air Lines

Home Depot

Johnson & Johnson

JPMorgan Chase & Co

Lowe's

Mind Medicine MindMed

Netflix

PayPal

Twitter

Wells Fargo

Walmart

Interested in Investing in Psychedelics? Check Out This Podcast.

ETFMG US Alternative Harvest ETF

Altria

AdvisorShares Pure US Cannabis ETF

Global X Cannabis ETF

AXS Cannabis ETF

Tilray Brands

Cambria Cannabis ETF

AdvisorShares Vice ETF

Pure Cannabis ETF

Alan Brochstein, a friend of the podcast and now a 3peat guest, is the founder of 420 Investor and New Cannabis Ventures. Thoughts on uplisting, the ETF MSOS, volume and valuation issues and confronting the California cannabis landscape.

Alan Brochstein: The Longer Legislation Takes, The Better For Cannabis Companies (Podcast)

The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has approved GW Pharmaceuticals' cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC) for patients two years of age and older. GW is a part of Jazz Pharmaceuticals plc (NASDAQ: JAZZ).

GW Pharmaceuticals' Cannabidiol For Seizures Wins UK Approval

Patients suffering from glioblastoma, the most common, deadly and extremely aggressive type of brain cancer, may have a chance of living longer if Sativex, a cannabis-based mouth spray, proves effective in treating recurrent brain tumors. Cancer charities and the UK's National Health Services (NHS) are launching a study to determine whether Sativex combined with chemotherapy medication –temozolomide – can help kill glioblastoma tumor cells and extend the overall length of patients' lives, reported The Guardian.

Cannabis-Based Sativex Mouth Spray To Treat Brain Tumors? Trial Gets Underway In England With Backing From National Health Services And Cancer Charities

Jazz Pharmaceuticals Plc updated its guidance for 2021 to reflect its acquisition of GW Pharmaceuticals Inc., which closed in early May. Jazz now expects revenue of $3.02 billion to $3.18 billion in 2021, compared with its previous guidance (as of May 4) of $2.55 billion to $2.70 billion.

Jazz updates 2021 guidance after closing acquisition of GW Pharmaceuticals

Jazz Pharmaceuticals

NEW YORK, June 4, 2021 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of California, Ziegler v. GW Pharmaceuticals, PLC et al, Docket No.

Monteverde & Associates PC Filed A Class Action Lawsuit On Behalf Of Shareholders Of GW Pharmaceuticals, PLC In The Southern District Of California

Arena Pharmaceuticals

HEXO Corp

FSD Pharma

OrganiGram Holdings Inc.

22nd Century Group

cbdMD Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in 2021.

What Happened with Marijuana Stocks This Week?

The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH).

Jazz Pharmaceuticals Closes On Acquisition Of GW Pharma, Adds CBD Drug Epidiolex To Portfolio

The developer of cannabis-based medications is now under new ownership.

Jazz Pharmaceuticals' Acquisition of GW Pharmaceuticals Closes

DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc

Jazz Pharmaceuticals said Tuesday it's on track to buy GW Pharmaceuticals early this month, and Jazz stock jumped despite a mixed first-quarter report. Sales missed, but earnings beat.

Jazz Expects To Buy GW Pharma — This Month — And Eyes Breakout

GW's ground-breaking medicines development programme recognised for outstanding achievement in innovation with UK's highest official award for British business GW's ground-breaking medicines development programme recognised for outstanding achievement in innovation with UK's highest official award for British business

GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation

AbbVie

Are Medical Marijuana Stock Going To Make Investors Rich In The Future? The post Top Medical Marijuana Stocks In 2021? 2 For Your May Watchlist appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Top Medical Marijuana Stocks In 2021? 2 For Your May Watchlist

Jazz is about to get the top cannabis-derived drug on the market, in addition to a robust pipeline.

GW Pharmaceuticals Stockholders Approve Acquisition by Jazz Pharmaceuticals

LONDON and DUBLIN, April 23, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW's shareholders voted to approve the acquisition of GW by a subsidiary of Jazz (or its nominee(s)) at the GW shareholder meetings held today. The proposals required to be approved by GW's shareholders in order to complete the acquisition were each approved. In addition, the non-binding, advisory proposal to approve certain compensation arrangements for GW's named executive officers was approved. Detailed information regarding the results will be made available by GW in a filing with the U.S. Securities and Exchange Commission (SEC).

GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals

Aphria

Corbus Pharmaceuticals Holdings

Neptune Wellness Solutions Inc.

Turning Point Brands

Village Farms International

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.

4/20 Holiday Week Had These Cannabis Stocks Fired Up

Weed stocks are red hot right now due to Democratic control of Congress and the White House as well as a recent spate of state cannabis legalizations. The post The 7 Top Weed Stocks From Q1 That You Should Know About appeared first on InvestorPlace.

The 7 Top Weed Stocks From Q1 That You Should Know About

Marijuana inhalables and edibles aren't the only things on the market anymore.

Check Out These 2 Innovative Cannabis Stocks That Are Cornering Hot New Markets

Marijuana stocks may still have some roadblocks until the U.S. market opens, but change is coming, and medical marijuana is leading the way. The post 7 Medical Marijuana Stocks For Your Waiting Room appeared first on InvestorPlace.

7 Medical Marijuana Stocks For Your Waiting Room

GW Pharmaceuticals PLC (NASDAQ:GWPH), the medicinal cannabis giant, has received European Commission (EC) approval for the treatment of seizures associated with tuberous sclerosis complex. The EC has approved the Type II variation application for GW's EPIDYOLEX (cannabidiol) as an adjunctive treatment of seizures for patients two years old or older.

GW Pharmaceuticals says its cannabis-based treatment for seizures gets another regulatory green light in Europe

– Tuberous sclerosis complex (TSC) represents a third indication for GW's cannabidiol in Europe –

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex

EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting

2020 was a big year for the cannabis industry, but 2021 is shaping up to be even bigger.

A Cannabis Pro Tells Us Her Hopes for the Medical Marijuana Industry

News for GW Pharmaceuticals Stock (GWPH)